Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07132333

Molecular Inflammation Board at the Center for Personalized Medicine

Molecular Inflammation Board at the Center for Personalized Medicine

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Psoriasis (PsO) Arthritis Bone Diseases Colitis Colitis, Ulcerative Colonic Diseases Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) Inflammatory Bowel Diseases Intestinal Diseases Joint Diseases Musculoskeletal Diseases Psoriasis Psoriasis Arthritis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital of Tübingen - Center for Personalized Medicine

Tübingen, 72076, Germany

Location status: Recruiting

Location contact

Fee Schmitt, Dr.

CONTACT

[email protected]

+4970712981240

About this study

Molecular Inflammation Board at the Center for Personalized Medicine

The study objectives are:

To ensure a prospective documentation of all patients who are referred to the Molecular Inflammation Board in routine clinical care To prospectively ensure the documentation of MEB patients with an emphasis to clinical outcome parameters and further response assessments (e.g. peripheral immunmonitoring, imaging parameters) To prospectively assess patient-reported outcome of MEB patients To evaluate compliance to MEB suggestions in routine clinical care

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic inflammatory disorder (PsO, PsA, SpA, IBD)
  • Given informed consent
  • 18 years of age

Exclusion criteria

  • No capacity to consent

Treatment and study plan

Biologic Agent

Biological

Intervention with biologic agents

Primary outcomes

  1. Therapy persistence

    Time frame: Through study completion, an average of 1 year

    Duration of intervention with biological agent

Study contacts

Contact information is provided by the study sponsor or research team.

Nisar P Malek, Prof. Dr.

CONTACT

[email protected]

+4970712982722

Sponsors and collaborators

Lead sponsor

University Hospital Tuebingen

Other

Collaborators

  • University Hospital Freiburg
  • University Hospital Heidelberg
  • University Hospital Ulm

Registry information

Official study title

The Molecular Inflammation Board at the Centers for Personalized Medicine at the University Hospitals of Freiburg, Heidelberg, Tübingen and Ulm - A Multicenter Prospective Observational Study

Acronym: MEB@ZPM

Important dates

Study start
2022
Primary completion
2032
Study completion
2032
First posted
Aug 20, 2025
Registry last updated
Aug 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.